Switch to:

Ratios

vs
industry
vs
history
PE Ratio 23.33
IHE's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 23.33 )
Ranked among companies with meaningful PE Ratio only.
IHE' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 23.33
0
30.97
PE Ratio without NRI 23.33
IHE's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 23.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
IHE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 23.33
0
30.97
PB Ratio 2.58
IHE's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 2.58 )
Ranked among companies with meaningful PB Ratio only.
IHE' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.23
Current: 2.58
0
3.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.84
IHE's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 0.84 )
Ranked among companies with meaningful Dividend Yield % only.
IHE' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 0.84
0
1.1
5-Year Yield-on-Cost % 0.84
IHE's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 0.84 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
IHE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 0.84
0
1.1

More Statistics

Short Percentage of Float0.00%
52-Week Range $129.41 - 156.52
Shares Outstanding (Mil)5,000,000.00
» More Articles for IHE

Headlines

Articles On GuruFocus.com
Some Highlights From Warren Buffett’s Annual Letter 2016 Feb 25 2017 
National Health Investors: 5% Yielding Dividend Achiever With Growth Up Ahead Feb 25 2017 
How General Motors Finished 2016 on a Positive Note Feb 25 2017 
Plan Your Trades and Trade Your Plan Feb 25 2017 
Heineken Releases Annual Report Feb 24 2017 
NIC: Supreme Business, but Large Contract Renewals Warrant Caution Feb 24 2017 
Eldorado Gold Reports 2016 Results Feb 24 2017 
Baron Perspective: Don’t Get Bitten by Biases Feb 24 2017 
Jana Partners Eats Breakfast With Tiffany Feb 24 2017 
HollyFrontier Reports 4th-Quarter 2016 Results Feb 24 2017 

More From Other Websites
Wall Street Analysts’ Estimates for Merck & Co. Feb 24 2017
Merck & Co. Reported Flat Operational Revenues in 4Q16 Feb 22 2017
Q4 Earnings Faring Well for Pharma ETFs Feb 06 2017
Novartis’s 4Q16 Earnings Meet Analysts’ Estimates Feb 01 2017
How to Play Pfizer's Fourth-Quarter Results With ETFs Feb 01 2017
Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug Jan 31 2017
Bristol-Myers Squibb: 4Q16 Earnings Show Growth Jan 30 2017
What Are Analysts’ Future Estimates for Johnson & Johnson? Jan 30 2017
Johnson & Johnson Reports Growth in 4Q16 Jan 26 2017
How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16? Jan 20 2017
What Lies Ahead for Pharma ETFs? Jan 19 2017
Biotech ETFs: When Will The Pain End? Jan 17 2017
Mylan’s Recent Commercial and Product Developments Jan 13 2017
Biotech ETFs Continue To Bleed Jan 12 2017
Mylan’s EpiPen Controversy: Is It a Brand or a Generic? Jan 11 2017
Biotech, Pharma ETFs Sink; Trump Promises "Bidding Procedures" Jan 11 2017
Top 5 Pharmaceutical ETFs for 2016 Dec 21 2016
Horizon Pharma’s Orphan Drug Segment: 3Q16 Performance Dec 20 2016
Trending: Transportation and Steel Industries Prepare for Trumponomics Dec 15 2016
Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space Dec 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK